SQSTM1 and metabolic syndrome: Recently, we reported that p62-encoding plasmid administered intramuscularly reduces levels of pro-inflammatory cytokines, increases levels of anti-inflammatory cytokines and mitigates inflammation-related diseases such as osteoporosis and metabolic syndrome [17,18].